Keryx's Long-Awaited Merger With Akebia Complete [Seeking Alpha]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Seeking Alpha
Two Heads Are Better Than One Akebia Therapeutics ( AKBA ) recently announced that their shareholders voted to approve the share issuance proposal required to complete the merger with Keryx Biopharmaceuticals ( KERX ). The merger, completed on December 12th, 2018, offers up to $250M in potential cost savings and combined kidney disease expertise all under one roof (Figure 1). More than 95% of the shares voted at the special meeting voted in favor of the share issuance proposal. It is clear this was the best opportunity for both companies moving forward. John P. Butler will remain CEO, while Keryx has appointed Adrian Adams as chairman. The two companies will unite together as one to fight chronic kidney disease opening new opportunities for accelerated growth. This new biotech combination also opens up an enticing opportunity for investors going into the new year. (Figure 1) Merger Sets Up Potential For A Leading Team In The Fight Against Kidney Diseas
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia [Yahoo! Finance]Yahoo! Finance
- CNN values your feedback [CNN]CNN
- Thinking about buying stock in Ocugen, Akebia Therapeutics, Mind Medicine, SoundHound AI, or Canopy Growth?PR Newswire
- Stocks Set To Close Blowout Week, Month And Quarter At All-Time High; Gold Soars To Record [zero hedge]zero hedge
- Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis [Yahoo! Finance]Yahoo! Finance
AKBA
Earnings
- 3/14/24 - Beat
AKBA
Sec Filings
- 3/15/24 - Form 8-K
- 3/14/24 - Form 10-K
- 3/14/24 - Form 8-K
- AKBA's page on the SEC website